Showing 5531-5540 of 6035 results for "".
- Neurolign Acquires of Eye Diagnostic Technology Company Neuro Kineticshttps://modernod.com/news/neurolign-acquires-of-eye-diagnostic-technology-company-neuro-kinetics/2476981/Neurolign Technologies announced the acquisition of Neuro Kinetics of Pittsburgh, Pennsylvania, a provider of clinical eye-tracking and noninvasive neurofunctional diagnostic testing, delivering neurofunctional assessments. Terms of the deal were not disc
- Orasis Pharmaceuticals Announces CSF-1 Eye Drop Successfully Met Primary Endpoint in Phase 2b Clinical Study in Presbyopiahttps://modernod.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia/2476977/Orasis Pharmaceuticals announced its CSF-1 eye drop has successfully met the primary endpoint in a phase 2b clinical study in individuals with presbyopia. CSF-1 successfully demonstrated statistically sig
- Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstenthttps://modernod.com/news/ivantis-completes-enrollment-of-international-spectrum-registry-for-hydrus-microstent/2476973/Ivantis announced that it has completed enrollment in its SPECTRUM, which the company calls the largest single-device registry in ophthalmology. SPECTRUM is a patient registry for the Hydrus Microstent, a microinvasive glaucoma surgery (MIGS) device to treat patients with mild to moderate
- LLamasoft Partners with Global Eye Bank, Eversighthttps://modernod.com/news/llamasoft-partners-with-global-eye-bank-eversight/2476974/LLamasoft has announced its partnership with Eversight, a nonprofit organization dedicated to restoring sight and preventing blindness through eye donation, corneal transplantation, and vision research. Eversight will utilize LLamasoft’s solutions to make data-driven decisions that more accuratel
- ProQR Announces Positive Topline Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patientshttps://modernod.com/news/proqr-announces-positive-topline-results-from-the-phase-1-2-study-of-sepofarsen-in-lca10-patients/2476975/ProQR Therapeutics announced positive topline results from the PQ-110-001 study, a phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported toda
- Ocutrx Unveils ORLenz for Surgery Visualization Technology in ARWear Headsethttps://modernod.com/news/ocutrx-unveils-orlenz-for-surgery-visualization-technology-in-arwear-headset/2476972/Ocutrx Vision Technologies is revealing a next-generation AR headset technology for surgery visualization called the ORLenz. A prototype of this technology is being formally introduced at the American Academy of Ophthalmology 2019 Conference in San Francisco. The ORLenz is a second medical device
- Canon USA to Showcase Eyecare Solutions At AAOhttps://modernod.com/news/canon-usa-to-showcase-eyecare-solutions-at-aao/2476971/Canon U.S.A. will be showcasing the recently FDA 510(k) cleared Xephilio OCT-A1 Optical Coherence Tomography device, together with the required RX Capture software, computer and LCD monitor,collectively, the “Xephilio OCT-A1 System, at the American Academy o
- QuickSee Handheld Autorefractor Shows Strong Agreement With Subjective Refraction Measurementshttps://modernod.com/news/quicksee-handheld-autorefractor-shows-strong-agreement-with-subjective-refraction-measurements/2476968/PlenOptika, maker of the QuickSee handheld autorefractor, announced the publication of research showing their device produces measurements in strong agreement with subjective refraction and traditional autorefraction technology. The paper “<
- Ex-Shire CEO Flemming Ornskov Emerges as Galderma CEO after $10B Nestlé Spinouthttps://modernod.com/news/ex-shire-ceo-flemming-ornskov-emerges-as-galderma-ceo-after-10b-nestle-spinout/2476966/As Takeda folds in Shire, two of the Irish rare disease specialist’s former top leaders have found themselves a new home at Nestlé skin health spinoff Galderma, according to a report in FiercePharma. Flemming Ornskov, Shire’s most recent CEO before the Takeda buyout, has
- Alcon to Highlight AcrySof IQ PanOptix Trifocal IOL Launch and New IOL Data at AAOhttps://modernod.com/news/alcon-to-highlight-acrysof-iq-panoptix-trifocal-iol-launch-and-groundbreaking-iol-data-at-aao/2476961/Alcon announced its plans to lead a wide range of informational and peer-to-peer educational programs at the American Academy of Ophthalmology (AAO) annual meeting on October 12-15 in San Francisco. The newly launched AcrySof IQ PanOptix Trifocal IOL, along with findings from the AAO IRIS (Intell